Last mentioned: Feb 23, 2026
Tarsus Pharmaceuticals outperformed revenue expectations with $151.6M in sales driven by XDEMVY, while ORIC Pharmaceuticals showcased clinical resilience with a narrowed loss and key oncology pipeline updates.
Tarsus Pharmaceuticals exceeded revenue expectations with $151.6 million in Q4 2025, driven by the commercial expansion of XDEMVY, while ORIC Pharmaceuticals demonstrated clinical-stage fiscal discipline with a narrowed quarterly loss. These results highlight the divergent financial profiles of commercial-stage specialty pharma versus pipeline-focused oncology developers.